Treatment regimens for pregnant women with falciparum malaria

References

• Takem EN, D’Alessandro U. Malaria in pregnancy. Mediterr J Hematol Infect Dis. 2013;5:e2013010.
   PubMedGoogle Scholar
• Dellicour S, Tatem AJ, Guerra CA, et al. Quantifying the number of pregnancies at risk of malaria in 2007: a demographic study. PLoS Med. 2010;7:e1000221.
   PubMed Web of Science ®Google Scholar
• Desai M, ter Kuile FO, Nosten F, et al. Epidemiology and burden of malaria in pregnancy. Lancet Infect Dis. 2007;7:93–104.
   PubMed Web of Science ®Google Scholar
• McGready R, Lee SJ, Wiladphaingern J, et al. Adverse effects of falciparum and vivax malaria and the safety of antimalarial treatment in early pregnancy: a population-based study. Lancet Infect Dis. 2012;12:388–396.
   PubMed Web of Science ®Google Scholar
• Rijken MJ, McGready R, Boel ME, et al. Malaria in pregnancy in the Asia-Pacific region. Lancet Infect Dis. 2012;12:75–88.
   PubMed Web of Science ®Google Scholar
• Menendez C, Ordi J, Ismail M, et al. The impact of placental malaria on gestational age and birth weight. J Infect Dis. 2000;181:1740–1745.
   PubMed Web of Science ®Google Scholar
• Sevene E, Gonzalez R, Menendez C. Current knowledge and challenges of antimalarial drugs for treatment and prevention in pregnancy. Expert Opin Pharmacother. 2010;11:1277–1293.
   PubMed Web of Science ®Google Scholar
• Manyando C, Mkandawire R, Puma L, et al. Safety of artemether-lumefantrine in pregnant women with malaria: results of a prospective cohort study in Zambia. Malar J. 2010;9:249.
   PubMed Web of Science ®Google Scholar
• White NJ, McGready RM, Nosten FH. New medicines for tropical diseases in pregnancy: catch-22. PLoS Med. 2008;5:e133.
   PubMed Web of Science ®Google Scholar
• Nosten F, McGready R, d’Alessandro U, et al. Antimalarial drugs in pregnancy: a review. Curr Drug Saf. 2006;1:1–15.
   PubMedGoogle Scholar
• Ward SA, Sevene EJP, Hastings IM, et al. Antimalarial drugs and pregnancy: safety, pharmacokinetics, and pharmacovigilance. Lancet Infect Dis. 2007;7:136–144.
   PubMed Web of Science ®Google Scholar
• Li Q, Weina PJ. Severe embryotoxicity of artemisinin derivatives in experimental animals, but possibly safe in pregnant women. Molecules. 2009;15:40–57.
   PubMed Web of Science ®Google Scholar
• World Health Organisation. Assessment of the safety of artemisinin compounds in pregnancy. Geneva: World Health Organisation; 2006.
   Google Scholar
• Clark RL. Embryotoxicity of the artemisinin antimalarials and potential consequences for use in women in the first trimester. Reprod Toxicol. 2009;28:285–296.
   PubMed Web of Science ®Google Scholar
• Poespoprodjo JR, Fobia W, Kenangalem E, et al. Dihydroartemisinin-piperaquine treatment of multidrug resistant falciparum and vivax malaria in pregnancy. PloS One. 2014;9:e84976.
   PubMed Web of Science ®Google Scholar
• Pregact Study Group, Pekyi D, Ampromfi AA, Tinto H, et al. Four artemisinin-based treatments in african pregnant women with malaria. N Engl J Med. 2016;374:913–927.
   PubMed Web of Science ®Google Scholar
• Moore KA, Simpson JA, Paw MK, et al. Safety of artemisinins in first trimester of prospectively followed pregnancies: an observational study. Lancet Infect Dis. 2016;16:576–583.
   PubMed Web of Science ®Google Scholar
• Dellicour S, Desai M, Aol G, et al. Risks of miscarriage and inadvertent exposure to artemisinin derivatives in the first trimester of pregnancy: a prospective cohort study in western Kenya. Malar J. 2015;14:461.
   PubMed Web of Science ®Google Scholar
• Manyando C, Njunju EM, Virtanen M, et al. Exposure to artemether-lumefantrine (Coartem) in first trimester pregnancy in an observational study in Zambia. Malar Jl. 2015;14:77.
   PubMed Web of Science ®Google Scholar
• Sangare LR, Weiss NS, Brentlinger PE, et al. Patterns of anti-malarial drug treatment among pregnant women in Uganda. Malar J. 2011;10:152.
   PubMed Web of Science ®Google Scholar
• Mosha D, Mazuguni F, Mrema S, et al. Safety of artemether-lumefantrine exposure in first trimester of pregnancy: an observational cohort. Malar J. 2014;13:197.
   PubMed Web of Science ®Google Scholar
• Laochan N, Zaloumis SG, Imwong M, et al. Intervals to Plasmodium falciparum recurrence after anti-malarial treatment in pregnancy: a longitudinal prospective cohort. Malar J. 2015;14:221.
   PubMed Web of Science ®Google Scholar
• Visser BJ, van Vugt M, Grobusch MP. Malaria: an update on current chemotherapy. Expert Opin Pharmacother. 2014;15:2219–2254.
   PubMed Web of Science ®Google Scholar
• Dawes M, Chowienczyk PJ. Drugs in pregnancy. Pharmacokinetics in pregnancy. Best Pract Res Clin Obstet Gynaecol. 2001;15:819–826.
   PubMed Web of Science ®Google Scholar
• Anderson GD. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin Pharmacokinet. 2005;44:989–1008.
   PubMed Web of Science ®Google Scholar
• Anderson GD. Using pharmacokinetics to predict the effects of pregnancy and maternal-infant transfer of drugs during lactation. Expert Opin Drug Metab Toxicol. 2006;2:947–960.
   PubMed Web of Science ®Google Scholar
• McGready R, Stepniewska K, Lindegardh N, et al. The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malaria. Eur J Clin Pharmacol. 2006;62:1021–1031.
   PubMed Web of Science ®Google Scholar
• McGready R, Stepniewska K, Ward SA, et al. Pharmacokinetics of dihydroartemisinin following oral artesunate treatment of pregnant women with acute uncomplicated falciparum malaria. Eur J Clin Pharmacol. 2006;62:367–371.
   PubMed Web of Science ®Google Scholar
• Tarning J, Rijken MJ, McGready R, et al. Population pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated malaria. Antimicrob Agents Chemother. 2012;56:1997–2007.
   PubMed Web of Science ®Google Scholar
• Tarning J, McGready R, Lindegardh N, et al. Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria. Antimicrob Agents Chemother. 2009;53:3837–3846.
   PubMed Web of Science ®Google Scholar
• McGready R, Stepniewska K, Edstein MD, et al. The pharmacokinetics of atovaquone and proguanil in pregnant women with acute falciparum malaria. Eur J Clin Pharmacol. 2003;59:545–552.
   PubMed Web of Science ®Google Scholar
• Karunajeewa HA, Salman S, Mueller I, et al. Pharmacokinetic properties of sulfadoxine-pyrimethamine in pregnant women. Antimicrob Agents Chemother. 2009;53:4368–4376.
   PubMed Web of Science ®Google Scholar
• Green MD, van Eijk AM, van Ter Kuile FO, et al. Pharmacokinetics of sulfadoxine-pyrimethamine in HIV-infected and uninfected pregnant women in Western Kenya. J Infect Dis. 2007;196:1403–1408.
   PubMed Web of Science ®Google Scholar
• Nyunt MM, Adam I, Kayentao K, et al. Pharmacokinetics of sulfadoxine and pyrimethamine in intermittent preventive treatment of malaria in pregnancy. Clin Pharmacol Ther. 2010;87:226–234.
   PubMed Web of Science ®Google Scholar
• Rijken MJ, McGready R, Phyo AP, et al. Pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated falciparum malaria. Antimicrob Agents Chemother. 2011;55:5500–5506.
   PubMed Web of Science ®Google Scholar
• Adam I, Tarning J, Lindegardh N, et al. Pharmacokinetics of piperaquine in pregnant women in Sudan with uncomplicated Plasmodium falciparum malaria. The Am J Trop Med Hyg. 2012;87:35–40.
   PubMed Web of Science ®Google Scholar
• Hoglund RM, Adam I, Hanpithakpong W, et al. A population pharmacokinetic model of piperaquine in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum malaria in Sudan. Malar J. 2012;11:398.
   PubMed Web of Science ®Google Scholar
• Benjamin JM, Moore BR, Salman S, et al. Population pharmacokinetics, tolerability and safety of dihydroartemisinin-piperaquine and sulfadoxine-pyrimethamine-piperaquine in pregnant and non-pregnant Papua New Guinean women. Antimicrob Agents Chemother. 2015;59:4260–4271.
   PubMed Web of Science ®Google Scholar
• Rijken MJ, McGready R, Jullien V, et al. Pharmacokinetics of amodiaquine and desethylamodiaquine in pregnant and postpartum women with Plasmodium vivax malaria. Antimicrob Agents Chemother. 2011;55:4338–4342.
   PubMed Web of Science ®Google Scholar
• Tarning J, Chotsiri P, Jullien V, et al. Population pharmacokinetic and pharmacodynamic modeling of amodiaquine and desethylamodiaquine in women with Plasmodium vivax malaria during and after pregnancy. Antimicrob Agents Chemother. 2012;56:5764–5773.
   PubMed Web of Science ®Google Scholar
• Davis TM, Moore BR, Salman S, et al. Use of quantitative pharmacology tools to improve malaria treatments. Expert Rev Clin Pharmacol. 2016;9:303–316.
   PubMed Web of Science ®Google Scholar
• Mutabingwa TK, Adam I. Use of artemether-lumefantrine to treat malaria during pregnancy: what do we know and need to know? Expert Rev Anti-infect Ther. 2013;11:125–135.
   PubMed Web of Science ®Google Scholar
• Kovacs SD, Rijken MJ, Stergachis A. Treating severe malaria in pregnancy: a review of the evidence. Drug Saf. 2015;38:165–181.
   PubMed Web of Science ®Google Scholar
• WHO. Guidelines for the treatment of malaria. 3rd ed. Geneva: World Health Organization; 2015.
   Google Scholar
• Dondorp A, Nosten F, Stepniewska K, et al. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet. 2005;366:717–725.
   PubMed Web of Science ®Google Scholar
• Dondorp AM, Fanello CI, Hendriksen IC, et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet. 2010;376:1647–1657.
   PubMed Web of Science ®Google Scholar
• Sinclair D, Donegan S, Isba R, et al. Artesunate versus quinine for treating severe malaria. Cochrane Database Syst Rev. 2012;(6):CD005967.
   Google Scholar
• McGready R, Phyo AP, Rijken MJ, et al. Artesunate/dihydroartemisinin pharmacokinetics in acute falciparum malaria in pregnancy: absorption, bioavailability, disposition and disease effects. Br J Clin Pharmacol. 2012;73:467–477.
   PubMed Web of Science ®Google Scholar
• Kloprogge F, McGready R, Phyo AP, et al. Opposite malaria and pregnancy effect on oral bioavailability of artesunate - a population pharmacokinetic evaluation. Br J Clin Pharmacol. 2015;80:642–653.
   PubMed Web of Science ®Google Scholar
• Davis TM, Mueller I, Rogerson SJ. Prevention and treatment of malaria in pregnancy. Future Microbiol. 2010;5:1599–1613. .
   PubMed Web of Science ®Google Scholar
• Davis TM. Antimalarial drugs and glucose metabolism. Br J Clin Pharmacol. 1997;44:1–7.
   PubMed Web of Science ®Google Scholar
• Davis TM, Suputtamongkol Y, Spencer JL, et al. Glucose turnover in pregnant women with acute malaria. Clin Sci (Lond). 1994;86:83–90.
   PubMed Web of Science ®Google Scholar
• Phillips RE, Looareesuwan S, White NJ, et al. Quinine pharmacokinetics and toxicity in pregnant and lactating women with falciparum malaria. Br J Clin Pharamcol. 1986;21:677–683.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Guidelines for treatment of malaria in the United States; 2013 [cited 2016 May]. Available from: http://www.cdc.gov/malaria/resources/pdf/treatmenttable.pdf
   Google Scholar
• Wong RD, Murthy AR, Mathisen GE, et al. Treatment of severe falciparum malaria during pregnancy with quinidine and exchange transfusion. Am J Med. 1992;92:561–562.
   PubMed Web of Science ®Google Scholar
• Morris CA, Onyamboko MA, Capparelli E, et al. Population pharmacokinetics of artesunate and dihydroartemisinin in pregnant and non-pregnant women with malaria. Malar J. 2011;10:114.
   PubMed Web of Science ®Google Scholar
• Tarning J, Kloprogge F, Piola P, et al. Population pharmacokinetics of artemether and dihydroartemisinin in pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda. Malar J. 2012;11:293.
   PubMed Web of Science ®Google Scholar
• Kloprogge F, Piola P, Dhorda M, et al. Population pharmacokinetics of lumefantrine in pregnant and nonpregnant women with uncomplicated Plasmodium falciparum malaria in Uganda. Clin Pharmacol Ther. 2013;2:e83.
   Google Scholar
• Tarning J, Kloprogge F, Dhorda M, et al. Pharmacokinetic properties of artemether, dihydroartemisinin, lumefantrine, and quinine in pregnant women with uncomplicated plasmodium falciparum malaria in Uganda. Antimicrob Agents Chemother. 2013;57:5096–5103.
   PubMed Web of Science ®Google Scholar
• Valea I, Tinto H, Traore-Coulibaly M, et al. Pharmacokinetics of co-formulated mefloquine and artesunate in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum infection in Burkina Faso. J Antimicrob Chemother. 2014;69:2499–2507.
   PubMed Web of Science ®Google Scholar
• Mosha D, Guidi M, Mwingira F, et al. Population pharmacokinetics and clinical response for artemether-lumefantrine in pregnant and nonpregnant women with uncomplicated Plasmodium falciparum malaria in Tanzania. Antimicrob Agents Chemother. 2014;58:4583–4592.
   PubMed Web of Science ®Google Scholar
• Kayentao K, Guirou EA, Doumbo OK, et al. Preliminary study of quinine pharmacokinetics in pregnant women with malaria-HIV co-infection. Am J Trop Med Hyg. 2014;90:530–534.
   PubMed Web of Science ®Google Scholar
• Kloprogge F, Jullien V, Piola P, et al. Population pharmacokinetics of quinine in pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda. J Antimicrob Chemother. 2014;69:3033–3040.
   PubMed Web of Science ®Google Scholar
• Nyunt MM, Nguyen VK, Kajubi R, et al. Artemether-lumefantrine pharmacokinetics and clinical response is minimally altered in Ugandan pregnant women treated for uncomplicated Plasmodium falciparum malaria. Antimicrob Agents Chemother. 2015;60:1274–1282.
   PubMed Web of Science ®Google Scholar
• Mosha D, Mazuguni F, Mrema S, et al. Medication exposure during pregnancy: a pilot pharmacovigilance system using health and demographic surveillance platform. BMC Preg Childbirth. 2014;14:322.
   PubMed Web of Science ®Google Scholar
• Adam I, Ali DA, Alwaseila A, et al. Mefloquine in the treatment of falciparum malaria during pregnancy in Eastern Sudan. Saudi Med J. 2004;25:1400–1402.
   PubMed Web of Science ®Google Scholar
• McGready R, Thwai KL, Cho T, et al. The effects of quinine and chloroquine antimalarial treatments in the first trimester of pregnancy. Trans R Soc Trop Med Hyg. 2002;96:180–184.
   PubMed Web of Science ®Google Scholar
• McGready R, Ashley EA, Moo E, et al. A randomized comparison of artesunate-atovaquone-proguanil versus quinine in treatment for uncomplicated falciparum malaria during pregnancy. J Infect Dis. 2005;192:846–853.
   PubMed Web of Science ®Google Scholar
• Okombo J, Ohuma E, Picot S, et al. Update on genetic markers of quinine resistance in Plasmodium falciparum. Mol Biochem Parasitol. 2011 Jun;177(2):77–82. PubMed PMID: 21295079.
   PubMed Web of Science ®Google Scholar
• Philipson A, Sabath LD, Charles D. Erythromycin and clindamycin absorption and elimination in pregnant women. Clin Pharmacol Ther. 1976;19:68–77.
   PubMed Web of Science ®Google Scholar
• McGready R, Cho T, Samuel VL, et al. Randomized comparison of quinine-clindamycin versus artesunate in the treatment of falciparum malaria in pregnancy. Trans R Soc Trop Med Hyg. 2001;95:651–656.
   PubMed Web of Science ®Google Scholar
• Chico RM, Chandramohan D. Quinine for the treatment of malaria in pregnancy. Lancet Infect Dis. 2010;10:140–141.
   PubMed Web of Science ®Google Scholar
• Djimde A, Lefevre G. Understanding the pharmacokinetics of Coartem. Malar J. 2009;8(Suppl 1):S4.
   PubMed Web of Science ®Google Scholar
• Cohen JL, Yavuz E, Morris A, et al. Do patients adhere to over-the-counter artemisinin combination therapy for malaria? Evidence from an intervention study in Uganda. Malar J. 2012;11:83.
   PubMed Web of Science ®Google Scholar
• McGready R, Tan SO, Ashley EA, et al. A randomised controlled trial of artemether-lumefantrine versus artesunate for uncomplicated plasmodium falciparum treatment in pregnancy. PLoS Med. 2008;5:e253.
   PubMed Web of Science ®Google Scholar
• Kay K, Hodel EM, Hastings IM. Improving the role and contribution of pharmacokinetic analyses in antimalarial drug clinical trials. Antimicrob Agents Chemother. 2014;58:5643–5649.
   PubMed Web of Science ®Google Scholar
• Piola P, Nabasumba C, Turyakira E, et al. Efficacy and safety of artemether-lumefantrine compared with quinine in pregnant women with uncomplicated Plasmodium falciparum malaria: an open-label, randomised, non-inferiority trial. Lancet Infect Dise. 2010;10:762–769.
   PubMed Web of Science ®Google Scholar
• Ukah M, Badejoko O, Ogunniyi S, et al. A randomized trial of artesunate-amodiaquine versus artemether-lumefantrine for the treatment of acute uncomplicated malaria in pregnancy. Int J Gynaecol Obstet. 2015;131:41–44.
   PubMed Web of Science ®Google Scholar
• Manyando C, Kayentao K, D’Alessandro U, et al. Safety and efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria during pregnancy: a systematic review. Malar J. 2012;11(Suppl 1):O39.
   PubMedGoogle Scholar
• European Medicines Agency (EMA). Eurartesim. EU summary of product characteristics; 2011 [cited 2016 May] Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/001199/WC500118117.pdf
   Google Scholar
• Poespoprodjo JR, Fobia W, Kenangalem E, et al. Treatment policy change to dihydroartemisinin-piperaquine contributes to the reduction of adverse maternal and pregnancy outcomes. Malar J. 2015;14:272.
   PubMed Web of Science ®Google Scholar
• Kakuru A, Jagannathan P, Muhindo MK, et al. Dihydroartemisinin-piperaquine for the prevention of malaria in pregnancy. N Engl J Med. 2016;374:928–939.
   PubMed Web of Science ®Google Scholar
• Batty KT, Moore BR, Stirling V, et al. Investigation of reproductive toxicity of piperaquine in mice. Reprod Toxicol. 2010;29:206–213.
   PubMed Web of Science ®Google Scholar
• Desai M, Gutman J, L’Lanziva A, et al. Intermittent screening and treatment or intermittent preventive treatment with dihydroartemisinin-piperaquine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for the control of malaria during pregnancy in western Kenya: an open-label, three-group, randomised controlled superiority trial. Lancet. 2015;386:2507–2519.
   PubMed Web of Science ®Google Scholar
• White NJ. Cardiotoxicity of antimalarial drugs. Lancet Infect Dis. 2007;7:549–558.
   PubMed Web of Science ®Google Scholar
• Na Bangchang K, Davis TM, Looareesuwan S, et al. Mefloquine pharmacokinetics in pregnant women with acute falciparum malaria. Trans R Soc Trop Med Hyg. 1994;88:321–323.
   PubMed Web of Science ®Google Scholar
• Nosten F, Karbwang J, White NJ, et al. Mefloquine antimalarial prophylaxis in pregnancy: dose finding and pharmacokinetic study. Br J Clin Pharmacol. 1990;30:79–85.
   PubMed Web of Science ®Google Scholar
• Karbwang J, Na Bangchang K, Thanavibul A, et al. Pharmacokinetics of mefloquine alone or in combination with artesunate. Bull World Health Organ. 1994;72:83–87.
   PubMed Web of Science ®Google Scholar
• McGready R, Brockman A, Cho T, et al. Randomized comparison of mefloquine-artesunate versus quinine in the treatment of multidrug-resistant falciparum malaria in pregnancy. Trans R Soc Trop Med Hyg. 2000;94:689–693.
   PubMed Web of Science ®Google Scholar
• Nosten F, van Vugt M, Price R, et al. Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study. Lancet. 2000;356:297–302.
   PubMed Web of Science ®Google Scholar
• Smithuis F, Kyaw MK, Phe O, et al. Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in falciparum malaria: an open-label randomised comparison. Lancet. 2006;367:2075–2085.
   PubMed Web of Science ®Google Scholar
• Tangpukdee N, Krudswood S, Chalermrut K, et al. An open, randomized clinical trial of Artekin(R) vs artesunate-mefloquine in the treatment of acute uncomplicated falciparum malaria. Southeast Asian J Trop Med Public Health. 2005;36:1085–1091.
   PubMedGoogle Scholar
• Hutagalung R, Paiphun L, Ashley EA, et al. A randomized trial of artemether-lumefantrine versus mefloquine-artesunate for the treatment of uncomplicated multi-drug resistant Plasmodium falciparum on the western border of Thailand. Malar J. 2005;4:46.
   PubMed Web of Science ®Google Scholar
• Gargano N, Ubben D, Tommasini S, et al. Therapeutic efficacy and safety of dihydroartemisinin-piperaquine versus artesunate-mefloquine in uncomplicated Plasmodium falciparum malaria in India. Malar J. 2012;11:233.
   PubMed Web of Science ®Google Scholar
• Nguyen TH, Day NP, Ly VC, et al. Post-malaria neurological syndrome. Lancet. 1996;348:917–921.
   PubMed Web of Science ®Google Scholar
• Nosten F, Vincenti M, Simpson J, et al. The effects of mefloquine treatment in pregnancy. Clin Infect Dis. 1999;28:808–815.
   PubMed Web of Science ®Google Scholar
• Steketee RW, Wirima JJ, Slutsker L, et al. Malaria treatment and prevention in pregnancy: indications for use and adverse events associated with use of chloroquine or mefloquine. Am J Trop Med Hyg. 1996;55(1 Suppl):50–56.
   PubMed Web of Science ®Google Scholar
• Schlagenhauf P, Blumentals WA, Suter P, et al. Pregnancy and fetal outcomes after exposure to mefloquine in the pre- and periconception period and during pregnancy. Clin Infect Dis. 2012;54:e124–e131.
   PubMed Web of Science ®Google Scholar
• Mutabingwa TK, Muze K, Ord R, et al. Randomized trial of artesunate+amodiaquine, sulfadoxine-pyrimethamine+amodiaquine, chlorproguanal-dapsone and SP for malaria in pregnancy in Tanzania. PloS One. 2009;4:e5138.
   PubMed Web of Science ®Google Scholar
• Tagbor HK, Chandramohan D, Greenwood B. The safety of amodiaquine use in pregnant women. Expert Opin Drug Saf. 2007;6:631–635.
   PubMed Web of Science ®Google Scholar
• World Health Organization, Global Malaria Programme. Updated WHO policy recommendation (October 2012): intermittent preventive treatment of malaria in pregnancy using sulfadoxine-pyrimethamine (IPTp-SP). Geneva: World Health Organization; 2012.
   Google Scholar
• Baraka V, Ishengoma DS, Fransis F, et al. High-level Plasmodium falciparum sulfadoxine-pyrimethamine resistance with the concomitant occurrence of septuple haplotype in Tanzania. Malar J. 2015;14:439.
   PubMed Web of Science ®Google Scholar
• Adjuik M, Babiker A, Garner P, et al. Artesunate combinations for treatment of malaria: meta-analysis. Lancet. 2004;363:9–17.
   PubMed Web of Science ®Google Scholar
• Shulman CE, Dorman EK, Cutts F, et al. Intermittent sulphadoxine-pyrimethamine to prevent severe anaemia secondary to malaria in pregnancy: a randomised placebo-controlled trial. Lancet. 1999;353:632–636.
   PubMed Web of Science ®Google Scholar
• Adam I, Ali DM, Abdalla MA. Artesunate plus sulfadoxine-pyrimethamine in the treatment of uncomplicated Plasmodium falciparum malaria during pregnancy in eastern Sudan. Trans R Soc Trop Med Hyg. 2006;100:632–635.
   PubMed Web of Science ®Google Scholar
• Kalilani L, Mofolo I, Chaponda M, et al. A randomized controlled pilot trial of azithromycin or artesunate added to sulfadoxine-pyrimethamine as treatment for malaria in pregnant women. PloS One. 2007;2:e1166.
   PubMed Web of Science ®Google Scholar
• Mishra N, Kaitholia K, Srivastava B, et al. Declining efficacy of artesunate plus sulphadoxine-pyrimethamine in northeastern India. Malar J. 2014;13:284.
   PubMed Web of Science ®Google Scholar
• Warsame M, Hassan AM, Barrette A, et al. Treatment of uncomplicated malaria with artesunate plus sulfadoxine-pyrimethamine is failing in Somalia: evidence from therapeutic efficacy studies and Pfdhfr and Pfdhps mutant alleles. Trop Med Int Health. 2015;20:510–517.
   PubMed Web of Science ®Google Scholar
• Chico RM, Chandramohan D. Intermittent preventive treatment of malaria in pregnancy: at the crossroads of public health policy. Trop Med Int Health. 2011;16:774–785.
   PubMed Web of Science ®Google Scholar
• Orton LC, Omari AA. Drugs for treating uncomplicated malaria in pregnant women. Cochrane Database Syst Rev. 2008;4:CD004912.
   Google Scholar
• Moore BR, Laman M, Salman S, et al. Naphthoquine: an emerging candidate for artemisinin combination therapy. Drugs. 2016;76:789–804.
   PubMed Web of Science ®Google Scholar
• Bukirwa H, Unnikrishnan B, Kramer CV, et al. Artesunate plus pyronaridine for treating uncomplicated Plasmodium falciparum malaria. Cochrane Database Syst Rev. 2014;(3):CD006404.
   Google Scholar
• Mathanga DP, Uthman OA, Chinkhumba J. Intermittent preventive treatment regimens for malaria in HIV-positive pregnant women. Cochrane Database Syst Rev. 2011;10:CD006689.
   Google Scholar
• Rogerson SJ, Wijesinghe RS, Meshnick SR. Host immunity as a determinant of treatment outcome in Plasmodium falciparum malaria. Lancet Infect Dis. 2010;10:51–59.
   PubMed Web of Science ®Google Scholar